



IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy in vitro

Friedrich Hahn¹, Christina Wangen¹, Sigrun Häge¹, Antonia Sophia Peter¹, Gerhard Dobler², Brett Hurst³, Justin Julander³, Jonas Fuchs⁴, Zsolt Ruzsics⁴, Klaus Überla¹, Hans-Martin Jäck⁵, Roger G. Ptak⁶, Andreas Muehler⁷, Manfred Gröppel⁷, Daniel Vitt⁷, Evelyn Peelen⁷, Hella Kohlhof^{7,&}, Manfred Marschall^{1,&}

¹ Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-Nürnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany

² Institute of Microbiology, Bundeswehr, Neuherbergstraße 11, 80937 München, Germany

³ Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322, USA

⁴ Institute for Virology, University Medical Center/Universitätsklinikum Freiburg, Hermann-Herder Str 11, 79104 Freiburg, Germany

⁵ Division of Immunology, Department of Medicine 3, FAU, Glückstraße 6, 91054 Erlangen, Germany ⁶ Drug Development Division, Infectious Disease Research, Southern Research, 431 Aviation Way, Frederick, Maryland 21701, USA ⁷ Immunic AG, Lochhamer Schlag 21, 82166 Gräfelfing, Germany [&] Both authors contributed equally to this study



www.med.fau.de

Funded by WSS MA/SBT 2018.121.1. Marohn-Stiftung Alz/Iko-Hahn/2019. DFG MA 1289/7-3

Hahn et al., Viruses 2020, 12(12), 1394; PMID 33291455